October 19, 2026 | Durban Dames

CBD, THC, CBG, CBN, HHC, THCP—and now EPN. The cannabinoid alphabet keeps growing, but a new name on a label does not necessarily mean a new discovery, a predictable experience, or a proven benefit.

Cannabinoids differ in their chemistry, how they are produced, and how much researchers know about them. Some can cause intoxication. Others generally do not produce a THC-like high. For many newer compounds, reliable human evidence is missing.

This guide separates what has been demonstrated from what remains uncertain, so you can ask better questions about the products you encounter.

Natural, semi-synthetic, and synthetic: what the terms mean

Cannabinoids Explained: Natural, Semi-Synthetic, Synthetic—and What We Know About EPN

First, what does “natural” actually mean?

Natural cannabinoids include compounds found in cannabis, called phytocannabinoids, and compounds made by the human body, called endocannabinoids.

Semi-synthetic cannabinoids are made by chemically modifying a naturally sourced starting material, such as hemp-derived CBD. They are also synthetic in the broader chemical sense; this guide uses a separate category to explain their origin.

Fully synthetic cannabinoids are manufactured through chemical synthesis rather than extracted from cannabis. This category includes prescription medicines, research compounds, and unregulated drugs. Those groups should not be treated as interchangeable.

Importantly, a molecule can occur naturally while a commercial supply of that same molecule is manufactured through conversion or synthesis. Delta-8 THC is a familiar example. “Hemp-derived” describes a starting source, not necessarily the entire production process.

How cannabinoids affect the body

The endocannabinoid system helps regulate functions including appetite, pain signaling, memory, and stress responses. CB1 and CB2 are two important cannabinoid receptors, but cannabinoids can also interact with other biological targets.

THC’s action at CB1 contributes to its intoxicating effects. Other cannabinoids have different patterns of activity. Laboratory activity does not automatically establish a useful treatment in humans, and stronger receptor binding does not directly tell us how much stronger a person will feel.

How to read the tables

These tables cover major consumer-facing cannabinoids and representative prescription and research compounds. They are not an exhaustive inventory of every cannabinoid, isomer, metabolite, or synthetic analogue. There is no complete, scientifically supported “feeling chart” for all of them.

“Unknown” means a reliable human effect has not been established—not that the compound is inactive or safe. Natural classifications describe occurrence; where commercial production commonly differs, that distinction is stated.

Table 1: Familiar plant cannabinoids and their acid forms

On a phone, swipe the table sideways to view every column.

Evidence notes: THC and CBD have much stronger human evidence than most minor cannabinoids. CBG and CBN findings come from specific, limited trials and do not establish that every product containing those ingredients will produce the same result.

Table 2:          

Rare cannabinoids, converted products, and emerging names

For converted and novel compounds, the exact chemical identity and manufacturing route matter. A marketing name or “hemp-derived” statement does not answer either question.

What is EPN—and why does it need extra explanation?

EPN, also sold as “Euphorinol,” appears in current hemp-product marketing. However, the public descriptions reviewed for this article do not consistently identify the same kind of material.

One seller presents EPN as a distinct hemp-derived cannabinoid in a multi-ingredient product. Another supplier describes Euphorinol as a proprietary multi-cannabinoid blend.

That difference matters. A single molecule and a mixture require different documentation and cannot automatically share the same effect profile.

We could not verify a consistent chemical identity or locate peer-reviewed human clinical evidence establishing EPN’s claimed effects in this research. That is a limitation of the available evidence, not proof that no relevant information exists.

Before relying on an EPN claim, ask for the precise identity of each active ingredient, its concentration, the manufacturing description, and laboratory methods capable of identifying the claimed substances. A routine cannabinoid panel may not establish the identity of an unfamiliar ingredient.

Claims such as “no paranoia,” “no tolerance,” “safe,” or “will not appear on a drug test” require evidence. They should not be treated as guarantees.

Table 3:

Reading the evidence: CBG and CBN findings come from limited studies and do not establish the same effects for every product. Stronger receptor binding does not translate directly to a stronger human experience. Prescription synthetic medicines, converted hemp ingredients, and illicit Spice-type products are distinct cate

K2 and Spice are product names, not individual cannabinoids. Their ingredients can change. Serious reactions to unregulated synthetic cannabinoid receptor agonists include seizures, cardiovascular problems, kidney injury, and death.

Prescription synthetic medicines, converted hemp ingredients, and illicit Spice-type products are distinct categories. The word “synthetic” alone cannot tell you their risk, quality, or medical usefulness.

Your body makes cannabinoids, too

Endocannabinoids made by your body

Anandamide and 2-arachidonoylglycerol, often called 2-AG, are natural endocannabinoids. They participate in signaling within the body rather than acting as familiar retail ingredients with a predictable “high.”

Their existence helps explain why cannabinoids can affect many functions. It does not mean that taking an outside cannabinoid automatically restores balance or treats a condition.

Why the same cannabinoid can feel different

Dose, route, product composition, tolerance, food intake, medications, and individual biology all influence the experience. A blended product also makes it difficult to attribute a feeling to one ingredient.

Non-intoxicating does not mean free of side effects. CBD, for example, can interact with medicines and cause drowsiness or liver injury. Avoid driving while impaired, keep products away from children and pets, and discuss cannabinoid use with a healthcare professional—especially during pregnancy, breastfeeding, or treatment for an ongoing condition.

Better education starts with better questions

Before buying, ask: What is the actual molecule? How was it produced? What does the batch report measure? Are the claimed effects supported by human research, or mainly by advertising?

At Durban Dames, we believe understanding those questions belongs at the beginning of the conversation.

For product-label education or a discussion about wholesale and white-label services, contact Durban Dames at 720-665-8227 or visit Go.DurbanDames.com.

Durban Dames — Elegantly Elevated.

Educational information only; not medical or legal advice. Inclusion does not indicate endorsement, availability, or legality. This guide does not provide dosing recommendations.

Sources and further reading

● FDA: CBD effects, medication interactions, and safety.

● NIDA: Cannabis effects and health risks.

● Zagzoog et al.: Laboratory and animal investigation of eight phytocannabinoids.

● CBG randomized human trial, 2024.

● CBN randomized sleep trial, 2024.

● THCV pilot trial in type 2 diabetes.

● Original THCP and CBDP isolation and pharmacology study.

● FDA: Delta-8 THC and conversion concerns.

● EUDA: Semi-synthetic cannabinoids and emerging markets.

● Cannabinoid acetate vaping experiment.

● Original cannabicitran isolation report.

● FDA: Cannabis-related prescription drug approvals.

● EUDA: Synthetic cannabinoid drug profile.

● CDC: Synthetic cannabinoid acute poisoning surveillance.

● AB-CHMINACA poisoning outbreak investigation.

● EUDA: 5F-MDMB-PINACA risk assessment.

● EPN product marketing example—documents seller claims, not independent proof.

● Euphorinol supplier description—documents blend marketing, not clinical evidence.